{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:38:37Z","timestamp":1761885517201,"version":"build-2065373602"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Integrase strand transfer inhibitors (INSTIs) are recommended in most first-line HIV treatment regimens. We describe a participant in a clinical trial with transmitted INSTI resistance. The participant had no history of INSTI use and had no evidence of INSTI exposure prior to HIV acquisition. Treatment with tenofovir disoproxil fumarate, lamivudine (3TC), and dolutegravir (DTG) was started 3 weeks after HIV diagnosis. Viral suppression was achieved within a year and was sustained for &amp;gt;3 years on treatment. Retrospective HIV genotyping of a pretreatment sample detected major resistance mutations in 3 drug classes, with predicted high-level resistance to DTG and 3TC. HIV phenotyping confirmed that the transmitted virus had DTG and 3TC resistance but retained susceptibility to DTG at higher drug concentrations. Pharmacologic testing indicated that the DTG concentrations observed in this case were sufficient to overcome the effects of 2 major baseline INSTI resistance mutations (G140S and Q148H).<\/jats:p>","DOI":"10.1093\/ofid\/ofaf645","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:04:31Z","timestamp":1760360671000},"source":"Crossref","is-referenced-by-count":0,"title":["Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate\/Lamivudine\/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7566-4213","authenticated-orcid":false,"given":"Hannah P","family":"Moore","sequence":"first","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-9000","authenticated-orcid":false,"given":"Jessica M","family":"Fogel","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1670-8786","authenticated-orcid":false,"given":"Mark A","family":"Marzinke","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]},{"name":"Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4890-1209","authenticated-orcid":false,"given":"Elias K","family":"Halvas","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4016-0629","authenticated-orcid":false,"given":"Urvi M","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W","family":"Mellors","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-5140","authenticated-orcid":false,"given":"Kerri J","family":"Penrose","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Seisa","sequence":"additional","affiliation":[{"name":"Monogram Biosciences , South San Francisco, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Petropoulos","sequence":"additional","affiliation":[{"name":"Monogram Biosciences , South San Francisco, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia L","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber","family":"Moser","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[{"name":"Statistical Center for HIV\/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marybeth","family":"McCauley","sequence":"additional","affiliation":[{"name":"FHI 360 , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Valencia-Huaman\u00ed","sequence":"additional","affiliation":[{"name":"Asociacion Civil Impacta Salud y Educacion , Lima ,","place":["Peru"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex R","family":"Rinehart","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-0711","authenticated-orcid":false,"given":"James F","family":"Rooney","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Soto-Torres","sequence":"additional","affiliation":[{"name":"Prevention Science Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Rockville, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[{"name":"Instituto de Pesquisa Clinica Evandro Chagas-Fiocruz , Rio de Janeiro ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1442-714X","authenticated-orcid":false,"given":"Raphael J","family":"Landovitz","sequence":"additional","affiliation":[{"name":"Center for Clinical AIDS Research and Education, University of California , Los Angeles, Los Angeles, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4587-791X","authenticated-orcid":false,"given":"Susan H","family":"Eshleman","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"author":"World Health Organization","key":"2025103023161554100_ofaf645-B1"},{"key":"2025103023161554100_ofaf645-B2"},{"key":"2025103023161554100_ofaf645-B3","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1089\/aid.2020.0261","article-title":"Integrase strand transfer inhibitor resistance in integrase strand transfer inhibitor-naive persons","volume":"37","author":"Bailey","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025103023161554100_ofaf645-B4","doi-asserted-by":"crossref","first-page":"718763","DOI":"10.3389\/fphar.2021.718763","article-title":"Transmitted drug resistance in antiretroviral therapy-naive persons with acute\/early\/primary HIV infection: a systematic review and meta-analysis","volume":"12","author":"Guo","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025103023161554100_ofaf645-B5","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/cid\/ciac972","article-title":"Transmitted drug resistance to integrase-based first-line human immunodeficiency virus antiretroviral regimens in Mediterranean Europe","volume":"76","author":"De Salazar","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025103023161554100_ofaf645-B6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1186\/s12879-023-08649-3","article-title":"Transmitted drug resistance and subtype patterns of viruses from reported new HIV diagnoses in Germany, 2017\u20132020","volume":"23","author":"Fiebig","year":"2023","journal-title":"BMC Infect Dis"},{"key":"2025103023161554100_ofaf645-B7","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/jac\/dkad109","article-title":"Increasing trend of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV","volume":"78","author":"Muccini","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025103023161554100_ofaf645-B8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/cid\/ciaf159","article-title":"Transmitted human immunodeficiency virus type 1 (HIV-1) drug resistance among newly diagnosed individuals in 31 provincial-level administrative divisions in China in 2023: a cross-sectional survey","volume":"81","author":"Hao","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025103023161554100_ofaf645-B9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2025103023161554100_ofaf645-B10","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/infdis\/jiab152","article-title":"Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083","volume":"224","author":"Marzinke","year":"2021","journal-title":"J Infect Dis"},{"key":"2025103023161554100_ofaf645-B11","doi-asserted-by":"crossref","first-page":"e0005323","DOI":"10.1128\/aac.00053-23","article-title":"Extended analysis of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083","volume":"67","author":"Marzinke","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025103023161554100_ofaf645-B12","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1016\/S2352-3018(23)00261-8","article-title":"Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial","volume":"10","author":"Landovitz","year":"2023","journal-title":"Lancet HIV"},{"key":"2025103023161554100_ofaf645-B13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/QAI.0000000000000172","article-title":"HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention","volume":"66","author":"Donnell","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025103023161554100_ofaf645-B14","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2025103023161554100_ofaf645-B15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/aid.2012.0089","article-title":"Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure","volume":"29","author":"Castillo-Mancilla","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025103023161554100_ofaf645-B16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/aid.2015.0182","article-title":"Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066)","volume":"32","author":"Hendrix","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025103023161554100_ofaf645-B17","doi-asserted-by":"crossref","first-page":"e01710","DOI":"10.1128\/AAC.01710-17","article-title":"Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy","volume":"62","author":"Anderson","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025103023161554100_ofaf645-B18"},{"key":"2025103023161554100_ofaf645-B19","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS One"},{"key":"2025103023161554100_ofaf645-B20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkz417","article-title":"Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance","volume":"75","author":"Tzou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025103023161554100_ofaf645-B21","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1128\/JCM.43.1.406-413.2005","article-title":"Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis","volume":"43","author":"Palmer","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2025103023161554100_ofaf645-B22","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1172\/JCI138099","article-title":"HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus","volume":"130","author":"Halvas","year":"2020","journal-title":"J Clin Invest"},{"key":"2025103023161554100_ofaf645-B23","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2025103023161554100_ofaf645-B24"},{"key":"2025103023161554100_ofaf645-B25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40121-014-0029-7","article-title":"Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV","volume":"3","author":"Dow","year":"2014","journal-title":"Infect Dis Ther"},{"key":"2025103023161554100_ofaf645-B26","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/AAC.05487-11","article-title":"Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility","volume":"56","author":"Melikian","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025103023161554100_ofaf645-B27","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/infdis\/171.6.1411","article-title":"Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)","volume":"171","author":"Schuurman","year":"1995","journal-title":"J Infect Dis"},{"key":"2025103023161554100_ofaf645-B28"},{"key":"2025103023161554100_ofaf645-B29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the international antiviral society\u2013USA panel","volume":"333","author":"Gandhi","year":"2025","journal-title":"JAMA"},{"key":"2025103023161554100_ofaf645-B30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf645\/64713264\/ofaf645.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf645\/64713264\/ofaf645.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf645\/64713264\/ofaf645.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:16:27Z","timestamp":1761880587000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf645\/8287118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf645","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,15]]},"article-number":"ofaf645"}}